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Hypofractionation for treatment of women with early breast
cancer is being used again after addressing past causes of
failure. Data from randomized trials confirm the safety and
efficacy of schedules using fraction sizes of around 3 Gy,
provided the correct downward adjustments to total dose
are made. Unjustified concerns relating to heart tolerance,
nonuniform dose distribution, and duration of follow-up
need not discourage the routine adoption of a 15- or 16-frac-
tion schedule. Potential benefits of the overall shorter treat-
ment time include greater convenience and improved local
tumor control, although the latter benefit remains to be
tested. Adjusting fraction size across the breast is a good
way of matching dose to tumor relapse risk. Amodest reduc-
tion in fraction size to breast tissue remote from the tumor
bed and at low risk of local tumor relapse is expected to re-
duce late adverse effects without significant loss of tumor
control. The corollary is that dose escalation to the index
quadrant, whether by hypofractionation or by a sequential
boost dose, will result in a greater relative increase in late ad-
verse effects than tumor control, a therapeutic disadvantage
that can be overcome only by exploiting a marked dose-
volume effect.
BRIEF HISTORY OF HYPOFRACTIONATION
Hypofractionation: What went wrong and why
It has been understood for more than 100 years that the re-
lationship between total radiation dose and biological effect
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1total dose must be reduced in order to maintain the same
level of antitumor or normal tissue effect. True, the dose re-
duction is relatively modest for epidermis and some tumors,
as correctly estimated by the Ellis isoeffect formula pro-
posed in the late 1960s (1). When a regimen is changed
from 25  2.0-Gy fractions to a 15-fraction regimen deliv-
ered over the same overall treatment time, the Ellis formula
estimated a dose reduction from 50 Gy to 45 Gy in 15 frac-
tions of 3.0 Gy to match acute skin reactions. Ellis felt that
the healing of skin epithelium reflected ‘‘the condition of
the underlying connective-tissue stroma’’ and, as a conse-
quence, he hypothesized that ‘‘apart from bone and
brain.the normal tissue tolerance dose, could be based on
skin tolerance.’’ It was realized in the late 1970s and early
1980s that dose reductions estimated using the Ellis formula
were insufficient for matching late side-effects (2–5). Late
effects such as subcutaneous fibrosis and skin
telangiectasia are more sensitive than acute reactions to
altered fraction size (6–7). In fairness, Ellis proposed his
formula as a hypothesis to be tested in the clinic, but
radiation oncologists applied the formula in what, with
hindsight, was an uncritical way.
The distinct fractionation sensitivities of early and late re-
sponding normal tissues are well described using a linear-
quadratic model in which an endpoint-specific quantity,
the a/b ratio, offers a reliable way of describing these differ-
ences (8–9). Assuming a typical a/b value of 3.0 Gy for late
normal tissue responses, a 15-fraction regimen reproducing
the effects of 25 fractions of 2.0 Gy requires a reduction in
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Table 1. Randomized clinical trials testing fraction size in adjuvant external beam radiotherapy
Trial year range
Test schedule
(total dose/fraction
no./treatment time
(weeks) (fraction size)) No. of patients
% of patients undergoing
breast-conserving surgery
% of patients prescribed
a boost dose
Median follow up
(months)
RMH/GOC
1986–1998
39.0/13/5.0 (3.0) 1,410 100 74.5 116
42.9/13/5.0 (3.3)
Ontario
1993–1996
42.5/16/3.2 (2.66) 1,234 100 0 > 132
STARTA
1999–2002
39.0/13/5.0 (3.0) 2,236 85 60.6* 61
41.6/13/5.0 (3.2)
START B
1999–2001
40.0/15/3.0 (2.67) 2,215 92 42.6* 72
Data compare designs of randomized clinical trials testing fraction size in adjuvant external beam radiotherapy to whole breast after local
excision of early breast cancer. All trials used a control arm delivering 50 Gy in 25 fractions over 5 weeks.
* Breast conservation patients only.
2 I. J. Radiation Oncology d Biology d Physics Volume 79, Number 1, 2011(10). The linear-quadratic model predicts that the Ellis for-
mula estimate of 45 Gy in 15 fractions is equivalent to 54
Gy in 2.0 Gy fractions, or to 56.3 Gy in the case of tissues
like the brachial plexus with an assumed a/b value of 2.0
Gy. Thus, using the Ellis formula for estimating biologically
isoeffective doses for late effects leads to an overdose of the
tissues where these effects are dose-limiting.
What recent trials show
It should now be clear that it is always possible to identify
a hypofractionated schedule equivalent to a conventionally
fractionated regimen in terms of a specific late adverse ef-
fect. For fraction sizes in the range of 1 to 6 Gy, the
linear-quadratic model appears to offer a reliable guide.
The next question is how local tumor control is affected.
It has long been assumed that most human tumors, espe-
cially squamous carcinomas, are relatively insensitive to
fraction size (6, 11). If correct, the sharp reduction in total
dose appropriate for late normal tissue effects leaves
tumors effectively underdosed. As a/b value estimatesTable 2. Randomised clinical trials testing fraction
Trial
Dose schedule
(total dose/fraction no./treatment time
(weeks) (fraction size))
Any c
app
RMH/GOC
1986–1998
50.0/25/5.0 (2.0)
39.0/13/5.0 (3.0)
42.9/13/5.0 (3.3)
Ontario
1993–1996
50.0/25/5.0 (2.0)
42.5/16/3.2 (2.66)
STARTA
1999–2002
50.0/25/5.0 (2.0)
39.0/13/5.0 (3.0)
41.6/13/5.0 (3.2)
START B
1999–2001
50.0/25/5.0 (2.0)
40.0/15/3.0 (2.67)
Results of randomised clinical trials testing fraction size in adjuvant ext
breast cancer. All trials used a control arm delivering 50 Gy in 25 fractio
* 71.3% and 69.8% at 10 years.
y 6.7% and 6.2% at 10 years.from human data became available, it turned out that
breast cancer and some other human malignancies appear
to be more sensitive to fraction size than previously
thought, comparable to the sensitivity of critical late
reacting normal tissues (11–13). The underlying cell and
molecular processes that explain these differences are not
clear, but a mechanistic understanding is not needed to
apply the linear-quadratic model safely and effectively.
Over the last 20 years, several randomized trials involving
a combined total of >7,000 women compared hypofractio-
nated adjuvant radiotherapy to a standard regimen of 50
Gy in 25 fractions (Tables 1 and 2) (14–19). UK Royal
Marsden Hospital/Gloucestershire Oncology Centre
(RMH/GOC) and Standardisation of Breast Radiotherapy
Trial A (START A) trials tested two dose levels of a 13-
fraction regimen in terms of late adverse effects and
tumor control; the study design allowed direct estimates of
a/b for each trial (15–17). Based on a combined total of
278 local-regional tumor relapses in the two trials, the ad-
justed a/b value for tumor control was 4.6 Gy (95%size in adjuvant external beam radiotherapy
5-year rate for
hange in breast
earance (%)
Good/excellent breast
cosmesis (%)
Local tumour
relapse (%)
35.4 – 12.1
27.4 – 14.8
42.3 – 9.6
– 79.2* 3.2y
– 77.9* 2.8y
42.9 – 3.2
32.1 – 4.6
43.6 – 3.2
42.2 – 3.3
36.5 – 2.0
ernal beam radiotherapy to whole breast after local excision of early
ns over 5 weeks.
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(95% CI, 2.3-4.5) for late change in photographic breast ap-
pearance. The two trials’ results suggested a 13-fraction reg-
imen delivered over 5 weeks can be as safe and as effective
as 50 Gy in 25 fractions.
Results from the Ontario and START B trials are consis-
tent with this interpretation. The Ontario trial compared
42.5 Gy in 16 fractions of 2.66 Gy (3.2 weeks) with 50 Gy
in 25 fractions over 5 weeks (14, 19). Schedules are
expected to be equivalent in terms of late normal tissue
and tumor responses assuming an a/b value of 3.0 Gy for
each and no influence of treatment time. Rates of breast
cosmesis at a median follow-up of >11 years were virtually
identical in both treatment arms, consistent with this expec-
tation. Given that tumor control might conceivably be sensi-
tive to a 2-week difference in treatment duration, it is not
possible to estimate tumor fractionation sensitivity from
these two trials. The UK START B trial compared 40 Gy
in 15 fractions of 2.67 Gy (3.0 weeks) to 50 Gy in 25 frac-
tions and recorded a lower rate of change in breast appear-
ance after the 15-fraction regimen (hazard ratio [HR] =
0.83; 95% CI, 0.66–1.04; p = 0.06) (17). An HR of <1 for
late adverse effects is likely to be real, since 40 Gy in 15 frac-
tions is equivalent to 45.5 Gy in 2.0-Gy fractions if the a/
b ratio = 3.0 Gy. In other words, 40 Gy in 15 fractions is gen-
tler on late reacting normal tissues than 50 Gy in 25 frac-
tions. The important question is whether it is also gentler
on breast cancer. If the a/b value for tumor control is $10
Gy, tumor control should be inferior after such a large reduc-
tion in total dose (from 50 Gy to 40 Gy), unless there is a ma-
jor effect of shortening overall time, but tumor control does
not appear to be worse. Although there were only 65 local-
regional tumor relapses in START B at the time of reporting,
the HR for this endpoint was 0.79 (95% CI, 0.48–1.29), in-
dicating similar rates of local-regional relapse after 40 Gy
in 15 fractions compared with 50 Gy in 25 fractions. The re-
sidual imprecision indicated by the upper and lower 95% CI
limits for the absolute difference between 40 Gy in 15 frac-
tions and the control schedule in START B suggests that
local-regional tumor relapse is unlikely to be more than
1% higher, and perhaps 1% or 2% lower, than after 50 Gy
in 25 fractions.
It is important to understand that population-based esti-
mates of the a/b value represent averages and that values
are likely to vary within tumor types as well as between
them. The goal of correlative research is to identify bio-
markers of fractionation sensitivity that can be used in the
clinic to stratify patients for hypofractionation. An un-
planned subgroup analysis of the Ontario trial suggested tu-
mor grade as a predictive factor for fractionation sensitivity,
but a statistically more powerful analysis of the UK START
fractionation trials did not confirm this (19–20). It has also
been speculated that a hypofractionated schedule may
leave less opportunity for reoxygenation and reassortment
due to the lower number of fractions, but these processes
are unlikely to play a major role in determining the
outcome of radiation therapy for subclinical disease.Results of clinical trials need to be applied to the popula-
tion from which patients were recruited, but there is no clin-
ical rationale for excluding underrepresented subgroups
without very good cause. In our view, hypofractionation tri-
als based predominantly on patients undergoing breast con-
servation surgery are informative for postmastectomy
radiotherapy. Local tumor relapse risks in the two surgical
groups are broadly comparable, according to the systematic
overview of radiotherapy effects by the Early Breast Cancer
Trialists Collaborative Group (21). For the 7,311 women en-
tered into randomized trials testing radiotherapy after breast
conservation surgery, the 10-year local relapse rate was
29.2% in node-negative patients and 46.5% in node-
positive patients in groups allocated to surgery without ra-
diotherapy. In 8,505 women with node-positive disease en-
tered into trials testing radiotherapy after mastectomy and
axillary clearance, local relapse at 10 years occurred in
29% of patients allocated to surgery without mastectomy.
Contemporary rates of local relapse after breast conservation
surgery and mastectomy are lower, due to the effects of ad-
juvant systemic therapies and other factors, but the principle
remains that the two surgical groups of patients are compa-
rable with respect to local relapse risk (22). In conclusion, on
the basis of level I evidence from four clinical trials, there
appears to be no reason to avoid modest hypofractionation
for the adjuvant treatment of women requiring whole-
breast or postmastectomy chest wall radiotherapy in any
identifiable subset of subclinical breast cancers. However,
there are some residual concerns expressed in the literature
that are immediately addressed below.
Concerns relating to organs at risk
All four clinical trials of hypofractionation provided pho-
tographs of breast appearance and reported palpable breast
induration. The most common change in breast appearance
is shrinkage (atrophy), but edema, retraction, and telangiec-
tasia also contribute. Change in breast appearance is a com-
plex phenotype, and the a/b estimate represents a synthesis
of different pathogenetic processes. Induration many years
after radiotherapy usually signifies underlying fibrosis, but
fat necrosis and breast edema contribute to induration scores
in the early years. Neither photographic appearance nor in-
duration records damage to underlying pectoral muscle or
rib cage. Prospective patient self-assessments of symptoms,
body image, and quality of life offer ways of assessing the
overall impact of these changes.
The sensitivity of lung tissue to larger fractions is a con-
cern, but lung doses delivered by tangential fields exceed tol-
erance in whatever fractionation schedule is used. It is
unusual for patients to develop clinically significant pneu-
monitis or fibrosis following radiotherapy confined to the
whole-breast (23, 24). Where the heart is concerned, the
priority is to protect this organ from exposure regardless of
radiation schedule, since there appears to be no safe lower
dose limit, however fractionated (25, 26).
After irradiation of the axilla and/or supraclavicular fossa,
there were no cases of brachial plexopathy recorded in 82
Fig. 1. Scatter plot of 5-year versus 10-year relative risk estimates
for late adverse effects (expressed as hazard ratios [HR]) after 42.9
Gy in 13 fractions relative to 50 Gy in 25 fractions, in the RMH/
GOC randomized breast radiotherapy fractionation trial (15).
HRs for 10 late endpoints were analyzed: any change in breast ap-
pearance, marked change in breast appearance, clinical assessment
of cosmesis, breast shrinkage, breast distortion, breast edema, indu-
ration, telangiectasia, arm edema, and shoulder stiffness. Error bars
indicate the estimate  standard error of 1, and the diagonal line is
the identity line, x = y. The figure shows that HRs at 5 years for these
10 late adverse effects tend to be lower than the HRs for the same
adverse effects at 10 years (p = 0.02, sign test).
Table 3. ‘‘Triple trouble’’ relative change in equivalent
doses
% equivalent dose in 2.0 Gy fractions at
different fraction sizes
Dose
inhomogeneity 2 Gy 3 Gy 4 Gy 5 Gy 6 Gy
105% 107.1% 107.1% 108.0% 108.3% 108.5%
110% 114.4% 115.5% 116.3% 116.9% 117.3%
115% 121.9% 123.6% 124.9% 125.8% 126.5%
‘‘Triple trouble’’ describes the relative change in the equivalent
dose in 2-Gy fractions as a function of magnitude of hot spot and
dose per fraction for hypofractionated schedules that are isoeffective
at the 100% reference point. For example, if 2.0 Gy is prescribed to
the 100% reference point, a 110% hot spot receives a 14.4% higher
dose, so if 25 fractions are prescribed, the 100% hot spot receives
114.4% of 50.0 Gy = 57.2 Gy. a/b = 3 Gy. Original plan was normal-
ized to 2 Gy per fraction at the 100% isodose contour.
4 I. J. Radiation Oncology d Biology d Physics Volume 79, Number 1, 2011patients given 40 Gy in 15 fractions in the START B trial at
a median follow-up of 6.0 years (interquartile range [IQR],
5.0–6.2 years) (18). The regimen is equivalent to 47 Gy in
2.0-Gy fractions if the a/b value for brachial plexus is 2.0
Gy or to 49 Gy in 2.0-Gy fractions, if a/b = 1.0 Gy. If radio-
therapy centers are confident that their technique is safe
when prescribing 50 Gy in 25 fractions, there will be no ex-
cess risk after 40 Gy in 15 fractions by using the same treat-
ment position, field arrangement, dosimetry, and reference
point.
Concern about duration of follow-up
The hypofractionation trials were published at median
follow-up times, varying from 5.1 years (IQR, 4.4–6.6 years)
in STARTA to 9.7 years (IQR, 7.8–11.8 years) in the RMH/
GOC trial, and >11 years in the Ontario trial (16, 17, 19).
New adverse effects, both nonstochastic and stochastic,
will appear for as long as patients are alive. However, the
critical concern is not whether a complete description of
adverse effects has been gained—it clearly has not. The
important question is whether the fractionation
sensitivities of responses developing at the time of
reporting are representative of those developing over the
entire life span of a patient.
Convincing evidence has been generated by European Or-
ganization for Research and Treatment of Cancer (EORTC)
trial 22881–10882, where the relative risk of induration at 5
years after tumor bed boost compared to no boost was com-
parable to that at 10 or more years, even though absolute
rates of induration increased in the interval (27). In the
RMH/GOC fractionation trial, 5-year and 10-year actuarial
estimates of the rates of 10 different late endpoints were pre-
sented (15). Figure 1 compares a scatter plot of 5-year versus
10-year relative risk estimates for several late effects in two
of the RMH/GOC trial arms, 42.9 Gy in 13 fractions relative
to 50 Gy in 25 fractions. As the incidence of various late tox-
icity endpoints were generally higher in the 42.9-Gy sched-
ule, these relative risk values are generally significantly
larger than 1. There is, however, no indication that the rela-
tive risk estimated at 10 years is higher than the risk esti-
mated at 5 years. On the contrary, all except one of the
data points fall below the identity line (x = y), consistent
with a relatively earlier onset of late effects after more in-
tense treatment, as previously observed for other data sets.
This observation is statistically significant as shown with
a two-tailed p value of 0.02 (sign test). In conclusion, it is un-
justified to consider follow-up a factor limiting the interpre-
tation of current hypofractionation trials (28).
Concern relating to ‘‘triple-trouble’’
‘‘Double trouble’’ was the term coined by Withers (29) to
illustrate the significance of a hot spot in a dose plan that re-
ceives not only a higher total dose but also a higher dose per
fraction. When fraction size is increased, the total dose needs
to be reduced, as already described. However, due to the
mathematical form of the linear-quadratic dose-effect rela-
tionship, hot spots will be penalized more severely in a hypo-fractionated treatment, a phenomenon called triple-trouble
(30). One way to look at this is by noticing that the steepness
of the dose-response curve increases with increasing dose
per fraction (31) and that this will tighten the required
dose uniformity. Table 3 shows the impact of dose in homo-
geneities on the dose intensity of hypofractionated regimens
that are isoeffectivewith 50 Gy in 25 fractions at a 100% ref-
erence point for whole-breast radiotherapy. For distributions
falling within International Commission on Radiation Units
and Measurements recommendations (95%-107% of refer-
ence isodose), triple-trouble has no clinically relevant
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a 2-Gy-per-fraction schedule. Even for hot spots of >110%,
evidence presented later (see section ‘‘A Strong Volume Ef-
fect’’ below) suggests a marked volume response for late ef-
fects such as breast shrinkage and induration. In other words,
the clinical consequences of high doses to small volumes are
much less than high doses delivered to large volumes.Other reasons for poor outcomes in the past
Inadequate downward adjustment to total dosewas not the
only factor contributing to poor historical results of hypo-
fractionated breast radiotherapy. Additional factors included
poor dosimetry and high skin doses delivered by low-energy
beams, use of nonstandard reference points, delivery of me-
dial and lateral tangential fields on alternate days, failure to
detect gross off-axis dose in homogeneities, and position er-
rors causing overlap at field junctions. With the benefit of
hindsight, it is easy to see how a prescribed mid-plane
dose to the breast of 2.5 Gy delivered as an applied dose
of 3.5 Gy to medial and lateral tangential cobalt-60 fields
on alternate days led to worse cosmetic results than if both
fields had been treated every day (32). Equally, it is now ob-
vious that changing patient position between fields greatly
increases the risk of overlap at field junctions and subsequent
harm to patients (33).Fig. 2. Dose-response curves for local tumor control (dashed line)
and for late photographic change in breast appearance (solid line) as
a function of dose delivered in 13 fractions. The upper dashed curve
is anchored at 70%, reflecting the proportion of patients predicted
to have no residual disease requiring eradication by radiotherapy,
i.e., patients controlled by surgery alone. The two solid points rep-
resent local control estimated after randomization to 39.0 Gy and
41.6 Gy in 13 fractions. The lower solid line represents the dose
response curve for late change in breast appearance in the same trial
(17).ACCELERATED FRACTIONATION MIGHT
IMPROVE TUMOR CONTROL, BUT RECOVERY
MUST BE COMPLETE BETWEEN FRACTIONS
Retrospective analyses of treatment delay raised the pos-
sibility that tumor proliferation may have been underesti-
mated in the past, with an estimated loss of 5-year survival
of 1.8 percentage points per month of delay over 1 to 6
months (34, 35). Other reports were consistent with this
finding, but an overview failed to detect a significant effect
(36–38). Treatment time has no impact on the risk of late
adverse effects, assuming a 24-hour interfraction interval
and complete repair (39, 40). Current protocols for
accelerated hypofractionation to partial breast, using three-
dimensional (3D) conformal radiotherapy, include twice-
daily fractions separated by 6 hours (41). Whatever the
schedule, a twice-daily schedule will have a greater biolog-
ical effect due to incomplete recovery. In the National Surgi-
cal Adjuvant Breast and Bowel Project B-39 trial (41), 38.5
Gy in 10 fractions delivered by external beam conformal ra-
diotherapy in twice-daily fractions, Monday to Friday of
a single week, delivers the equivalent of 53 Gy in 2.0-Gy
fractions, assuming complete repair and an a/b value of
3.4 Gy. If the recovery half-time for late effects is taken as
the 4.4 hours estimated for subcutaneous fibrosis in the Con-
tinuous Hyperfractionated Accelerated Radiotherapy head
and neck trial, the twice-daily schedule delivers the equiva-
lent of 65 Gy in 2-Gy fractions. The satisfactory interim cos-
metic results reported with this schedule suggest
a significant volume effect in sparing late adverse effects
(as discussed below) (42, 43).DOSE ESCALATION HAS A MUCH GREATER
EFFECT ON NORMALTISSUE RESPONSES THAN
ON TUMOR CONTROL AFTER WHOLE-BREAST
RADIOTHERAPY
The standard sigmoid dose-response models used in radia-
tion oncology are completely specified by two parameters:
a position parameter (often taken as the dose for 50% inci-
dence of the endpoint in question, theD50) and a steepness pa-
rameter, most often the normalized dose-response gradient,
g50 (44). The parameter g50 is defined as the absolute percent-
age increment in response rate per 1% increase in total dose at
the 50% response level (45). For normal tissues, typical values
forg50 lie between 2 and 4, so a 2.0-Gy increment in total dose
above 50 Gy in 25 fractions to the breast, representing a 4%
increase in total dose, causes an 8% to 16% absolute increase
in the probability of an adverse effect around the 50% response
level (46). Due to the sigmoid shape of the dose response, the
increase in incidence of an adverse effect occurring in 10% of
patients will be less dramatic. The g10 lies between 0.5 and
1.2, and the expected absolute increase in response from
a 4% increase in total dose will be 2% to 5% (47).
The dose response for control of subclinical tumor foci is
even shallower due to much greater heterogeneity in terms of
familiar factors known to influence tumor control probabil-
ity, including variation in clonogen number, intrinsic radio-
sensitivity, hypoxia, and repopulation. Systematic overviews
(21) of outcomes in patients treated with surgery alone sug-
gest that an average of 70%, perhaps more, of patients have
no residual disease in the breast at referral for radiotherapy,
so the dose response curve is actually anchored at 70%, not
0%, local control (Fig. 2). Dose response data from the
RMH/GOC and START A trials suggest a local g value of
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achieves a change in local tumor control of <1% (16,17).
There is a benefit here to be exploited in low-relapse-risk
patients. A reduction in total dose is expected to reduce the
complication risk by a much greater margin than local tumor
control. An 8% reduction in dose intensity from 50 Gy to 46
Gy in 2.0-Gy fractions to the whole breast is expected to in-
crease local tumor relapse by #1.5%. The absolute rate of
mild/moderate adverse effects will fall by up to 30%, and
for more marked effects occurring in up to 10% of cases,
the expected reduction will be at least 4%. These estimates
are consistent with the outcome of the UK START B trial,
in which a 15-fraction regimen equivalent to 46 Gy in 23
fractions in terms of late adverse effects was tested without
any significant inferiority in terms of tumor control (18).
It ought to be possible to take advantage of the differing
gradients of the dose response curves for late adverse effects
and tumor control to improve the therapeutic ratio in areas of
the breast at low risk of tumor relapse. This possibility is being
tested by reducing dose intensity outside the index quadrant in
the UK Intensity Modulated and Partial Organ Radiotherapy
(IMPORT) LOW trial of partial breast radiotherapy in women
>50 years old with unifocal invasive ductal carcinoma (Fig. 3a
and b). Patients are eligible if they are considered to have an
annual risk of local recurrence of <1%: those who are $50Fig. 3. Schemas of UK intensity modulated and partial breast
breast conservation surgery.years old, have any grade of unifocal invasive ductal carci-
noma #30 mm, and have 1 to 3 positive lymph nodes (48).
Compared to 15 fractions of 2.67 Gy delivered to the whole
breast (control), test arms 1 and 2 deliver 15 fractions of 2.4
Gy and zero dose, respectively, outside the index quadrant.
Applying an a/b value of 3 Gy, test arm 1 delivers the equiv-
alent to 40 Gy in 20 fractions to this volume, close to the
quasi-threshold dose for nonstochastic late adverse effects.
In contrast, improving tumor control by dose escalation in
higher risk patients depends on a very strong volume effect,
a requirement that will be considered next.A STRONG VOLUME EFFECT IS NEEDED TO
COMPENSATE FOR THE ADVERSE EFFECTS OF
DOSE ESCALATION, HOWEVER FRACTIONATED
The volume effect for a given endpoint is tested by compar-
ing adverse effects after randomization to different volumes of
breast tissue prescribed the same dose. If a volume effect exists,
it may vary according to the endpoint chosen. Indirect mea-
sures ofvolumeeffect for indurationcanbegained fromseveral
sources, including (i) a retrospective study of nonrandomized
variation in interstitial brachytherapy volumes and (2) a ran-
domized EORTC trial of boost dose versus no-boost dose fol-
lowingwhole-breast radiotherapy (49–50). In the retrospective(IMPORT) LOWand HIGH trials with women treated by
Hypofractionated whole-breast radiotherapy d J. YARNOLD et al. 7study of brachytherapy volumes, low-dose-rate iridium im-
plantation given as boost therapy after tumor excision and
whole-breast radiotherapy to 404 patients was associated
with a four-fold increase in risk of fibrosis (induration) for
each 100 cm3 increment in boost volume, suggesting a very
steep volume response (49). In the EORTC study of electron
boost therapy, univariate analysis of cosmesis in 364 patients
treated with boost volumes of #200 cm3 compared to >200
cm3 reported a HR of 0.45 (95% CI, 0.29-0.76), suggesting
a shallower volume response (50). Ameasure of thevolume ef-
fect can also be derived by comparing dose responses (g
values) for late adverse effects following a randomized boost
dose to the tumor bed compared with the same dose increment
to the whole-breast volume. This test was performed with 723
patients entered into the RMH/GOC fractionation trial, ran-
domized after whole-breast radiotherapy into thosewhowould
not receive a tumor bed boost versus those who would receive
a boost dose of 15.5 Gy (100%) in 7 fractions via a direct elec-
tronfield, typically 7 to 10 cmdiameter and 8 to 12MeVenergy
(15). In this trial, 27.5%of patients randomized to the no-boost
group developed moderate or marked induration at 10 years
compared to 44.5% of those randomized to receive boost ther-
apy, generating ag value of 0.5. The same trial randomized 940
patients to two dose levels of whole-breast radiotherapy using
a 13-fraction regimen (Table 1), generating a g value for indu-
rationof around1.4 at 10years after randomization.Thevolume
and proportion of breast irradiated with electron boost can only
be estimated crudely based on the above parameters, but values
correspond to about 200 cc3 and 25%, respectively. For this par-
tial volume, the slopeof thedose response for clinically assessed
induration is about one-third that of whole-breast radiotherapy.
The scope for exploiting a dose-volume effect in dose esca-
lation isundergoing testing in theUKIMPORTHIGHtrial, de-
signed for patients needing a tumor bed boost dose after breast
conservation surgery, appropriate adjuvant systemic therapy,
and whole-breast radiotherapy. The trial design compares se-
quential versus simultaneous integrated boost delivered to
a standardized target volume (Fig. 3c and d). The test arm 1
boost dose is equivalent to that of the control arm in terms of
late adverse effects, assuming an a/b value of 3.0 Gy. Thus,
40Gy in 15 fractions plus sequential 16Gy in 8 fractions (con-
trol) and 48 Gy in 15 fractions (test arm 1) to identical tumor
bed volumes are each equivalent to 60 Gy in 30 fractions. If
rates and severity of induration are comparable in both arms,
this shows that a reduction in dose from 40 Gy in 15 fractions
to 36 Gy in 15 fractions outside the index quadrant fails to in-
crease tolerance inside the boost volume. If the induration
score in test arm 2 is comparable to that in the control arm, itsuggests a large and quantifiable sparing effect from reducing
the dose to low-risk volumes. The reality may lie in between.
WHATARETHELIMITSOFHYPOFRACTIONATED
WHOLE-BREAST RADIOTHERAPY?
It is unlikely that a 15- or 16-fraction regimen represents
the limits of hypofractionation for whole-breast radiotherapy.
The UK prospective randomised clinical trial testing 5.7 Gy
and 6.0 Gy fractions of whole breast radiotherapy in terms
of late normal tissue responses and tumour control (FAST
trial) (51) randomized 915 women 50 years old or older
with node-negative tumors following breast conservation sur-
gery to receive whole-breast radiotherapy delivered using 3D
dosimetry to a total dose of 50Gy in 25 fractions (control) ver-
sus 28.5 or 30 Gy in 5 once-weekly fractions of 5.7 or 6.0 Gy
and no tumor bed boost. Assuming a/b = 4.0 Gy, the dose
levels are equivalent to 46 Gy and 50 Gy in 2.0 Gy fractions,
respectively. An interim analysis of moderate/marked breast
shrinkage (photographic assessment) generated an a/b of
2.4 Gy (95% CI, 1.0-3.9) consistent with estimates generated
by the STARTA trial (51). A schedule of 30 Gy in 5 fractions
over 15 days to the whole breast using 3D dosimetry reported
very mild acute reactions and satisfactory 2-year outcome in
terms of change in breast appearance and induration com-
pared to a matched sample of patients treated to 50 Gy in
25 fractions (52). This schedule is too intense to form the basis
of a 5-day schedule, given current estimates of a/b values de-
rived from the FAST and START trials, but a 5-day course of
whole-breast radiotherapy that delivers 1 fraction per day can
certainly be identified that is equivalent to standard fraction-
ation in terms of late adverse effects in the breast (but not
the lymphatic pathways). If the a/b value for late adverse ef-
fects is between 2 and 3 Gy and that for tumor control is be-
tween 4 and 5 Gy, a small loss of therapeutic gain might be
compensated for by a time factor for tumor control when
treatment times are compressed from 5 weeks to 1 week.
CONCLUSIONS
Recent randomized trials justify the routine use of modest
hypofractionation for adjuvant whole-breast radiotherapy in
women with early breast cancer. The standard UK schedule
of 40 Gy in 15 fractions is gentler on normal tissues than 50
Gy in 25 fractions, without evidence of inferior local tumor
control. This schedule, or 42.5 Gy in 16 fractions, can be rec-
ommended as safe and effective alternatives to 50 Gy in 25
fractions for whole-breast or postmastectomy chest wall ra-
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